Zero Candida (ZC), an innovative Israeli FemTech startup, is thrilled to announce the granting of its first intellectual property patent in South Africa (2022/09265) alongside a PCT patent (PCT-IL 2023050243). This milestone marks a significant step in the company’s journey to revolutionize the treatment of fungal infections affecting women.
The company is also moving towards listing on the TSX Venture Exchange in Canada, with an estimated valuation of 40 million Canadian dollars. This public listing is anticipated to provide the necessary capital for further expansion and development of their groundbreaking technology.
Zero Candida’s device, which utilizes a controlled “Blue Light,” offers a novel approach to treating fungal infections. This tampon-like device eradicates the fungus swiftly and effectively, without any side effects. Medical professionals highlight its potential to not only eliminate the infection but also prevent its recurrence, meeting the rising demand for non-chemical health solutions among women.
Eli Ben Haroosh, the founder and CEO, expressed his optimism: “This first Intellectual Property marks a great potential to the company as we expect to announce additional ones in the coming future. In addition, we will be able to start commercial sales in South Africa following the U.S. Food and Drug Administration (FDA) approval.”
“Zero Candida has a potential to become a technological leader and use its ground-breaking technology to expand boundaries of non-chemical candida treatment”. Added Ben Haroosh.
Echoing this sentiment, Dr. Asher Holtzer, a director at ZC, stated, “The invention of Zero Candida brings amazing news to FemTech women’s care and can become a leader in women’s health globally. According to medical studies, 75% of women will suffer during their lifetime from Candida disease, a fungal infection that attacks large parts of the female reproductive system, which causes significant damage to the quality of life and, in severe cases, even disability. Until now, the common treatments for candida included antifungal drugs that alleviated the symptoms but failed to solve the problem at its root.”
